The U.S. Food and Drug Administration has approved a new nonstimulant medication for attention deficit hyperactivity disorder, offering a fresh treatment option for children, adolescents and adults. The drug, centanafadine, marks the first new nonstimulant ADHD therapy to receive FDA approval in over a decade.
Centanafadine works by targeting three key brain chemicals involved in attention and impulse control. Unlike many existing ADHD medications, it inhibits the reuptake of norepinephrine, dopamine and serotonin, providing a broader mechanism of action. In clinical trials, the drug demonstrated significant reductions in ADHD symptoms compared to placebo, with a side effect profile that included mild to moderate events such as decreased appetite, headache and insomnia. The approval covers patients aged six years and older, making it a versatile option across the lifespan.
For patients and families, this approval adds an important alternative to the current ADHD treatment landscape. Many existing nonstimulant options are limited to specific age groups or come with significant side effects. Centanafadine’s once-daily dosing and its lack of abuse potential, common with stimulant therapies, may improve adherence and long-term management. The drug is expected to be particularly useful for individuals who cannot tolerate stimulants or have not responded well to other treatments.
What This Means for ADHD Care
The approval comes at a time when ADHD diagnoses are rising, and access to diverse treatment options remains a priority. The FDA’s decision was based on data from multiple phase 3 studies involving thousands of participants. Researchers noted that centanafadine showed consistent efficacy across age groups, with improvements in inattention, hyperactivity and impulsivity. The drug’s manufacturer is now preparing for commercial launch, and insurance coverage discussions are underway.
Looking ahead, clinicians expect centanafadine to become a first-line consideration for many patients, especially those seeking a nonstimulant approach. Ongoing studies are exploring its long-term safety and potential benefits in specific populations, such as individuals with co occurring anxiety or tic disorders. With this approval, the ADHD treatment toolbox gains a modern, well studied option that could help many patients achieve better symptom control and quality of life.